胎盘生长因子和可溶性 fms 样酪氨酸激酶 1 作为缺血性心脏病和心力衰竭的生物标志物：综述。
Placenta growth factor and sFlt-1 as biomarkers in ischemic heart disease and heart failure: a review.
机构信息
Department of Pharmaceutical & Administrative Sciences, Ellis Pharmacogenomics Lab, College of Pharmacy & Health Sciences, Drake University, Des Moines, IA 50311, USA.
Department of Medical Microbiology, Immunology, & Cell Biology, Department of OB/GYN, Southern Illinois University, School of Medicine, Springfield, IL 62702, USA.
出版信息
Biomark Med. 2019 Jun;13(9):785-799. doi: 10.2217/bmm-2018-0492. Epub 2019 Jun 3.
Coronary heart disease (CHD) and heart failure (HF) produce significant morbidity/mortality but identifying new biomarkers could help in the management of each. In this article, we summarize the molecular regulation and biomarker potential of PIGF and sFlt-1 in CHD and HF. PlGF is elevated during ischemia and some studies have shown PlGF, sFlt-1 or PlGF:sFlt-1 ratio, when used in combination with standard biomarkers, strengthens predictions of outcomes. sFlt-1 and PlGF are elevated in HF with sFlt-1 as a stronger predictor of outcomes. Although promising, we discuss additional study criteria needed to confirm the clinical usefulness of PlGF or sFlt-1 in the detection and management of CHD or HF.
冠心病（CHD）和心力衰竭（HF）会导致较高的发病率和死亡率，但识别新的生物标志物有助于这两种疾病的管理。在本文中，我们总结了 PIGF 和 sFlt-1 在 CHD 和 HF 中的分子调控和生物标志物潜力。在缺血期间 PlGF 升高，一些研究表明，PlGF、sFlt-1 或 PlGF:sFlt-1 比值与标准生物标志物联合使用时，可以增强对结局的预测。sFlt-1 和 PlGF 在 HF 中升高，sFlt-1 是结局的更强预测因子。尽管很有前景，但我们还讨论了在检测和管理 CHD 或 HF 中确认 PlGF 或 sFlt-1 的临床用途所需的额外研究标准。
Zotero 插件